ライフサイエンスコーパス: autoantibody-negative

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 yopathy who previously were considered to be autoantibody negative.

2 /IA-2 autoantibody-positive but anti-phogrin autoantibody-negative.

3 ctional and longitudinal analyses of healthy autoantibody-negative (AA(-)) high HLA-risk siblings (HR

4 dies (Ab(+)) and 40 age-matched persistently autoantibody negative (Ab(-)) control subjects.

5 We observed that autoantibody negative (Ab-) type 2 diabetic patients (n

6 in insulin sensitivity and secretion between autoantibody-negative (Ab-) and -positive (Ab+) youth wi

7 pond to corticosteroid therapy and represent autoantibody-negative autoimmune hepatitis.

8 nd the United Kingdom and enrolling 25 islet autoantibody-negative children aged 2 to 7 years with a

9 etes-associated autoantibodies (n = 18) with autoantibody-negative children matched for age, sex, ear

10 en cases of BCA were detected; 153 unrelated autoantibody-negative children were selected from the co

11 re not significantly different from those of autoantibody-negative control subjects.

12 ee relatives of the IDDM subjects, and in 28 autoantibody-negative control subjects.

13 ties, and air trapping, compared with 33% of autoantibody-negative controls (P = 0.005).

14 (a profile that is 96% specific for RA), 15 autoantibody-negative controls, and 12 patients with est

15 ependent diabetes syndrome, characterized by autoantibody-negative diabetes mellitus and skin deformi

16 evident both in autoantibody-positive and in autoantibody-negative disease.

17 tibody-positive RA but also with the risk of autoantibody-negative disease.

18 ty over its potential use in, and impact on, autoantibody-negative diseases.

19 red with concentrations in age-matched islet autoantibody-negative first-degree relatives of patients

20 ell cytoplasmic autoantibody- and/or insulin autoantibody-negative first-degree relatives of the IDDM

21 ibody positive group (P = 0.010) than in the autoantibody negative group.

22 hed control children who remained islet cell autoantibody-negative in follow-up.

23 Autoantibody-negative individuals (n = 171) served as a

24 o diabetes-predictive autoantibodies and 366 autoantibody-negative matched control children.

25 iabetes (progressors) and those who remained autoantibody negative, matched by age, sex, sample perio

26 e found in 26% of T1D subjects classified as autoantibody-negative on the basis of existing markers [

27 lizumab-treated recipients compared with GAD autoantibody-negative or ATG-treated recipients.

28 nterval [95% CI] 0.39-0.76) as compared with autoantibody-negative patients (OR 0.90, 95% CI 0.41-1.9

29 isease severity in autoantibody-positive and autoantibody-negative patients, respectively.

30 IDDM (6 of 9 [66%]; 3.9+/-3.2) compared with autoantibody-negative relatives (1 of 15 [7%]; 1.8+/-1.0

31 A comparison with 60 autoantibody-negative relatives suggested protection fro

32 The response in healthy control subjects, autoantibody-negative relatives, and IDDM patients, resp

33 mokine (C-X-C motif) ligand 10 compared with autoantibody-negative subjects.

34 Among islet autoantibody-negative women, breastfeeding was associate

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。